Neuland Laboratories Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Neuland Laboratories Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹100Over the last 3 years, every ₹100 of reported profit came with ₹100 of operating cash.
Lower than 52% of Healthcare companies in India.
Self-Funding Ratio
1.2×Over the last 3 years its own operating cash covered its investment spending (capex) 1.2 times.
Lower than 55% of Healthcare companies in India.
Cash Locked Ratio
₹38For every ₹100 of sales, ₹38 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹39 tied up three years earlier.
More money tied up than 73% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 2/3Sales grew in 2 of the last 3 years; profit grew in 2 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
₹26Sales grew 66% in 3 years; of every extra ₹100 of sales, ₹26 became extra profit.
Higher than 72% of Healthcare companies in India.
Asset Productivity Ratio
+66% / +85%In 3 years sales changed by +66% while total assets changed by +85%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
9.7×Debt due within a year is covered 9.7 times by its yearly operating cash.
Higher than 76% of Healthcare companies in India.
Cash Cushion Ratio
+0%Cash, after subtracting all debt, equals 0% of its market value (net cash).
Higher than 59% of Healthcare companies in India.
Tangible Assets Ratio
90%Of every ₹100 the company owns, ₹90 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 69% of Healthcare companies in India.
Tangible Net Worth Ratio
85%Of every ₹100 of net worth, ₹85 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 69% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Neuland Laboratories Limited owes ₹0.36 for every ₹1 it owns. Net profit rose 40% in the year to Mar 2026, and grew 31% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
48.6Investors pay ₹48.6 for every ₹1 of Neuland Laboratories Limited's yearly profit, higher than 68% of Healthcare companies in India.
P/B ratio
12.91The share price is 12.91 times Neuland Laboratories Limited's book value per share, higher than 92% of Healthcare companies in India.
Market cap
₹24,204 CrThe total market value of all of Neuland Laboratories Limited's shares at today's price (share price × number of shares), larger than 80% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹1,874 CrWhat Neuland Laboratories Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹1,461Net worth divided by the number of shares. The share price of ₹18,865 is 12.9 times this, which is the P/B above.
Return on equity (ROE)
26.6%Neuland Laboratories Limited earned 26.6% on its shareholders' money over the last year, higher than 90% of Healthcare companies in India.
Owes vs Owns
0.36×Neuland Laboratories Limited owes ₹0.36 for every ₹1 it owns (low), lower than 54% of Healthcare companies in India.
Dividend yield
0.16%Neuland Laboratories Limited pays 0.16% of its share price as dividends a year, lower than 75% of dividend-paying Healthcare companies in India.
Revenue growth
+35%Revenue rose 35% in the year to Mar 2026, and grew 19% a year on average over 3 years.
Profit growth
+40%Net profit rose 40% in the year to Mar 2026, and grew 31% a year on average over 3 years.
Profit margin
18.8%Neuland Laboratories Limited keeps ₹19 of every ₹100 of revenue as net profit.
Cash quality
0.95×Cash from Neuland Laboratories Limited's business was 0.95× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
26.2×Neuland Laboratories Limited's operating profit covered its interest costs 26.2 times in the year to Mar 2026.
Cash vs debt
Net cashNeuland Laboratories Limited held ₹25 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Neuland Laboratories Limited's P/E ratio?
Investors pay ₹48.6 for every ₹1 of Neuland Laboratories Limited's yearly profit, higher than 68% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Neuland Laboratories Limited: ₹24,204 Cr ÷ ₹1,874 Cr (31 Mar 2026) = 12.9.
What is Neuland Laboratories Limited's return on equity?
Neuland Laboratories Limited earned 26.6% on its shareholders' money over the last year, higher than 90% of Healthcare companies in India.
How much does Neuland Laboratories Limited owe compared with what it owns?
Neuland Laboratories Limited owes ₹0.36 for every ₹1 it owns (low), lower than 54% of Healthcare companies in India.
Does Neuland Laboratories Limited pay a dividend?
Yes. Neuland Laboratories Limited pays 0.16% of its share price as dividends a year, lower than 75% of dividend-paying Healthcare companies in India.
Is Neuland Laboratories Limited's revenue growing?
Revenue rose 35% in the year to Mar 2026, and grew 19% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.